The concept of microbiome-based therapeutics has generated significant enthusiasm within the medical science community, defining a new frontier in the field of medicine. Despite having captured the interest of several venture capital firms and big pharma players, no microbiome-based therapeutic has been officially approved by an authorized medical product regulator. However, the current development pipeline of microbiome therapeutics has several promising candidates that are likely to result in commercial success stories soon.

To order this 640+ page report, which features 235+ figures and 275+ tables, please visit this link

The USD 4 billion (by 2030) financial opportunity within the microbiome therapeutics (Tx) market and diagnostics (Dx) markets, has been analyzed across the following segments:
 Type of Therapy (Tx)
 Prescription Drug
 Prebiotics
 Probiotics

 Type of Molecule (Tx)
 Small Molecules
 Biologics

 Target Indication (Tx+Dx)
 Acne Vulgaris
 Atopic Dermatitis
 Clostridium difficile Infection
 Colorectal Cancer
 Crohn’s Disease
 Diabetes
 Irritable Bowel Syndrome
 Lactose Intolerance
 Lung Cancer
 Nonalcoholic steatohepatitis (NASH)
 Obesity
 Ulcerative colitis

 Therapeutic Area (Tx+Dx)
 Autoimmune Disorders
 Dental Disorders
 Digestive and Gastrointestinal Disorders
 Dermatological Disorders
 Infectious Disease
 Metabolic Disorders
 Oncology
 Others

 Key Geographical Regions (Tx+Dx)
 North America
 Europe
 Asia-Pacific and Rest of the World


The Human Microbiome Market, 2019-2030 report features the following companies, which we identified to be key players in this domain:
 4D Pharma
 Armata Pharmaceuticals
 Evelo Biosciences
 Rebiotix (Acquired by Ferring Pharmaceuticals)
 Seres Therapeutics
 Vedanta Biosciences

Table of Contents
1. Preface

2. Executive Summary

3. Introduction

4. Microbiome Therapeutics: Market Landscape

5. Company and Drug Profiles

6. Microbiome Diagnostics: Market Landscape

7. Fecal Microbiota Therapy (FMT)

8. Attractiveness Competitiveness (AC) Matrix

9. Microbiome Related Initiatives of Big Pharmaceutical Players

10. Start-up Health Indexing

11. Key Therapeutics Areas

12. Funding and Investment Analysis

13. Contract Services for Microbiome Therapeutics

14. Big Data and Microbiome Therapeutics

15. Microbiome Therapeutics: Market Forecast and Opportunity Analysis

16. Microbiome Diagnostics: Market Forecast and Opportunity Analysis

17. Fecal Microbiota Therapies: Market Forecast and Opportunity Analysis

18. Case Study: Microbiome-based Products in Other Industries

19. Concluding Remarks

20. Executive Insights

21. Appendix I: Tabulated Data

22. Appendix II: List of Companies and Organizations


To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/human-microbiome-market/281.html

Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
[email protected]